-
Mashup Score: 2
During the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the Multiple Myeloma Hub spoke to Katja Weisel, University Medical Center Hamburg-Eppendorf, Hamburg, DE. We asked, Which therapies are most frequently used in triple-exposed patients with multiple myeloma (MM)?
Source: multiplemyelomahub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1
During the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the Multiple Myeloma Hub spoke to Katja Weisel, University Medical Center Hamburg-Eppendorf, Hamburg, DE. We asked, Which therapies are most frequently used in triple-exposed patients with multiple myeloma (MM)?
Source: multiplemyelomahub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1
Mobilized peripheral blood stem cells on the bone marrow are important for a successful autologous hematopoietic cell transplantation (auto-HCT). As such, collecting sufficient numbers of CD34+ cells is critical for a robust hematopoietic recovery and sustained engraftment.
Source: multiplemyelomahub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1
During the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the Multiple Myeloma Hub spoke to Morie Gertz, Mayo Clinic, Rochester, US. We asked, How can patterns of immune reconstitution guide treatment early after transplant?
Source: multiplemyelomahub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Is it safe to perform ASCT in patients with renal insufficiency? - 2 year(s) ago
During the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the Multiple Myeloma Hub spoke to Laurent Garderet, Hôpital Pitié-Salpêtrière, Paris, FR. We asked, Is it safe to perform ASCT in patients with renal insufficiency?
Source: multiplemyelomahub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1
During the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the Multiple Myeloma Hub spoke to Morie Gertz, Mayo Clinic, Rochester, US. We asked, How can patterns of immune reconstitution guide treatment early after transplant?
Source: multiplemyelomahub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Allo-HSCT in patients with therapy-related AML or MDS - 2 year(s) ago
Therapy-related myeloid neoplasm (t-MN) is a secondary malignancy that can occur after being exposed to chemotherapy. 70% of t-MN cases appear 5–7 years after being treated with an alkylating agent, while the other 30% are diagnosed 2–3 years after treatment with topoisomerase II inhibitors (e.g., anthracyclines, etoposide).
Source: aml-hub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Is Isa+Kd efficacious in patients who have received prior ASCT? - 2 year(s) ago
During the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the Multiple Myeloma Hub spoke to Mohamad Mohty, Hôpital Saint-Antoine and Sorbonne University, Paris, FR. We asked, Is Isa+Kd efficacious in patients who have received prior autologous stem cell transplant (ASCT)?
Source: multiplemyelomahub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0How can CRISPR be used for adoptive T-cell therapy in AML? - 3 year(s) ago
During the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the AML Hub spoke to Eliana Ruggiero, IRCCS Ospedale San Raffaele, Milan, IT. We asked, How can CRISPR be used for adoptive T-cell therapy in AML?
Source: aml-hub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
During the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the AML Hub spoke to Norbert Vey, Institut Paoli-Calmettes, Marseille, FR. We asked, What challenges arise in the management of AML in complete remission?
Source: aml-hub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
⏰ In case you missed it ⏰ During #EBMT21, the MM Hub was pleased to speak with Katja Weisel, @uni_tue. We asked, Which therapies are most frequently used in triple-exposed patients with multiple #myeloma❓ #mmsm https://t.co/F7sbdXu4BS